1569: Evaluation of a Novel Drug to Treat Canine Cutaneous Lymphoma
Grant Status: Open
Canine lymphoma is one of the most common cancers encountered in veterinary oncology. While most canine multicentric lymphoma patients initially respond to currently available chemotherapy protocols, response rates are considerably lower in patients with cutaneous T cell lymphoma (CTCL), and generally brief in duration. In this study, Dr. Thamm will evaluate the effectiveness of a novel anti-cancer drug, GS-9219, in canine CTCL through the completion of a phase-II clinical trial. Successful demonstration of efficacy of GS-9219 against canine CTCL would provide an important drug in the veterinarian's armamentarium against this challenging disease.
Manuscript in preparation.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.